Personalized therapy for TARDBP ALS
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This trial offers a custom-made treatment for people with ALS caused by a TARDBP gene mutation. It uses a personalized medicine approach to target the specific genetic cause of the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a genetically confirmed neurological disorder, specifically ALS linked to TARDBP.
- You or your legal representative must agree to participate and sign a consent form.
- You must be able to travel to the study site for all follow-up visits and tests.
- You must not be using any other experimental medication within 5 half-lives before starting the trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized medicine approach for people with ALS caused by changes in the TARDBP gene. The treatment uses a custom-made molecule to target the genetic cause and may help slow the disease.
This study aims to better understand ALS by looking at your genes, biomarkers, and stem cells. It may help develop treatments that are personalized to you.
This trial tests a new type of cell therapy called regulatory T cells (Tregs) for people with neurodegenerative diseases like ALS. The goal is to see if these cells can slow down the disease.
This study tests an experimental gene therapy called XT-150, which is given as an injection into the fluid around the spinal cord. The goal is to see if it is safe and to gather information that could help treat ALS muscle weakness.
This study tests an investigational drug called ALT001 in people with amyotrophic lateral sclerosis (ALS), a disease that affects nerve cells controlling muscles. The goal is to see if ALT001 can help slow the progression of the disease. Participants will receive the drug and be monitored for safety and effects.
This study tests a new gene therapy called SNUG01 for people with ALS (a disease that weakens muscles). The goal is to see if it's safe and might slow down the disease, especially for those diagnosed within the last 2 years.
Hear when a new Amyotrophic Lateral Sclerosis (ALS) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.